Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
- Conditions
- Interventions
- Drug: RituximabDrug: FludarabineDrug: CyclophosphamideProcedure: Peripheral blood stem cell (PBSC) transplantationDrug: EtoposideGenetic: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cellsDrug: DoxorubicinProcedure: Allogeneic hematopoietic stem cell transplant (HSCT)Drug: VincristineDrug: FilgrastimDrug: PrednisoneGenetic: T-Rapa cell Donor Lymphocyte Infusion (DLI)
- First Posted Date
- 2003-12-15
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 442
- Registration Number
- NCT00074490
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 16
- Registration Number
- NCT00060346
- Locations
- 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00054665
- Locations
- 🇺🇸
Roswell Parck Cancer Institute, Buffalo, New York, United States
🇺🇸National Cancer Institute (NCI), Bethesda, Maryland, United States
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 854
- Registration Number
- NCT00003389
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 56
- Registration Number
- NCT00041132
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 571
- Registration Number
- NCT00006721
- Locations
- 🇺🇸
Northside Hospital Cancer Center, Atlanta, Georgia, United States
🇺🇸Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States
🇺🇸Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 30
- Registration Number
- NCT00031590
- Locations
- 🇺🇸
Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 76
- Registration Number
- NCT00026208
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸Kaiser Permanente Medical Center, Vallejo, California, United States
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
- First Posted Date
- 2003-01-08
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT00051311
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
- First Posted Date
- 2002-06-04
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00038610
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.